What's New
FTD in the News
Aviado Bio CMO Discusses ASPIRE-FTD Clinical Trial with Neurology Live
In a recent interview with Neurology Live, Aviado Bio chief medical officer David Cooper, MD, discussed the…
AFTD Brand Influencer Discusses Commitment to Caring
AFTD Brand Influencer Nicole Petrie shared her family’s FTD journey with host Lisa Opie on the podcast…
Study Investigates Incidence Rates of FTD and Other Young-Onset Dementias in Italy
A study published in the journal Diagnosis, Assessment & Disease Monitoring investigates the incidence of neurodegenerative young-onset…
AFTD Grant Recipient Discusses Gene Therapy for FTD-GRN on Canadian TV
In an interview with the Canadian Broadcasting Corporation, Dr. Simon Ducharme of McGill University in Montreal discussed…
ASPIRE-FTD Phase 1/2 Clinical Trial Opens First US Site at Ohio State University
Biopharmaceutical company AviadoBio announced on July 1 that its ASPIRE-FTD phase 1/2 clinical trial has opened its…
Care Partner Emphasizes the Benefits of Support from Others Who Understand FTD
Navigating the FTD journey is much less daunting when you have support from others who have lived…
Opinion Column Highlights Racial Disparities in Dementia Care and Need for Support
An opinion column published in the Los Angeles Daily News highlights healthcare-based racial disparities that often leave…
A Conversation with Olga Uspenskaya, MD, PhD, of Prevail Therapeutics
Recently, Prevail Therapeutics presented interim results from their Phase 1/2 open-label clinical trial assessing the safety and…
Passage Bio Receives Positive Feedback from FDA on Expanding Gene Therapy to C9orf72
Biopharmaceutical company Passage Bio announced on July 16 that it has received positive feedback from the U.S….
Researcher Explains the Role of Genetics in FTD, Discusses Avenues for Treatment
In an article written for The Conversation, Fen-Biao Gao, PhD, professor and founding director of the FTD…